



# Investor Presentation

Half-Year 2026 Results

February 2026

**Treatment focused.**  
**Technology driven.**

personal use only

or

# Disclaimer

This document has been prepared as a summary only and does not contain all information about SomnoMed Limited's (the Company's) assets and liabilities, financial position and performance, profit and losses and the rights and liabilities attaching to the Company's securities. This document should be read in conjunction with any public announcements and reports (including financial reports and disclosure documents) released by the Company. The securities issued by the Company are considered speculative and there is no guarantee that they will make a return on the capital invested, that dividends will be paid on the Shares or that there will be an increase in the value of the Shares in the future.

Some of the statements contained in this release are forward-looking statements. Forward looking statements include but are not limited to, statements concerning estimates of future sales, expected revenues and costs, statements relating to the continued advancement of the Company's operations and other statements which are not historical facts. When used in this document, and on other published information of the Company, the words such as "aim", "could", "estimate", "expect", "intend", "target", "forecast", "future", "will", "may", "potential", "should" and similar expressions are forward-looking statements.

Although the company believes that its expectations reflected in the forward-looking statements are reasonable, such statements involve risk and uncertainties and no assurance can be given that actual results will be consistent with these forward-looking statements. Various factors could cause actual results and projections of future performance to differ from these forward-looking statements as a result of known and unknown risks, uncertainties and other factors not anticipated by the Company or disclosed in the Company's published material. Many of these factors are beyond the control of the Company Limited and may involve subjective judgement and assumptions as to future events, which may or may not be correct.

The Company does not purport to give financial or investment advice. No account has been taken of the objectives, financial situation or needs of any recipient of this document.

Recipients of this document should carefully consider whether the securities issued by the Company are an appropriate investment for them in light of their personal circumstances, including their financial and taxation position.


# Half-Year 2026 Results

1. 1H FY26 Highlights

2. Financials

3. Operations update

4. FY26 outlook



personal use only

# 1H FY26 Highlights

## Revenue

**\$60.7m**

+13% vs pcp<sup>2</sup>  
of \$53.7m

## EBITDA<sup>1</sup>

**\$7.8m**

+35% vs pcp of  
\$5.8m

## Capex

**\$3.4m**

vs pcp of  
\$1.4m

## Operating cash flow<sup>3</sup>

**\$2.5m**

vs pcp of \$2.7m

## Free cash flow<sup>4</sup>

**(\$0.9m)**

vs pcp of \$1.3m

## Cash balance

**\$18.0m**

+4% vs  
30 June 2025 of  
\$17.3m

Figures throughout the presentation are denominated in AUD, unless otherwise stated.

<sup>1</sup>EBITDA excludes leases payments (\$1.6m), share/option expenses (\$1.5m), unrealised foreign exchange gain/(loss) (\$0.5m), one-off costs (\$0.6m - tranche 3 restructure) and discontinued operations (nil).

<sup>2</sup>PCP is the prior comparative period of 31 December 2024.

<sup>3</sup>Operating cash flow of \$2.5m represents statutory operating cash flow of \$4.1m less \$1.6m of lease costs and includes the impact of \$0.8m of one-off costs.

<sup>4</sup>FCF represents operating cash flow including lease costs less capex spend.

# SomnoMed's Opportunity

## VISION

A world where our oral appliance therapy is the standard of care for sleep apnea treatment.

## MISSION

As the global leader in oral appliance therapy, we set the standard for outcomes, innovation and patient experience – driving the transformation of sleep medicine worldwide.

## INVESTMENT HIGHLIGHTS



Significant total addressable market with 900+ million individuals suffering from OSA globally.



Increasing consumer awareness, growth in GLP-1 drugs, and demand for CPAP alternatives is growing the OAT market.



SomnoMed is the market leader in oral appliances for the treatment of OSA.



Advancing the development of Rest Assure, the first technology-enabled oral device.


# Half-Year 2026 Results

1. 1H FY26 Highlights


**2. Financials**

3. Operations update

4. FY26 outlook



# Record Half Year Revenue



## Revenue growth

- Record 1H FY26 revenue of \$60.7m
- Revenue growth of +13% vs pcp.
- Continued strong growth across Europe and North America.

## Earnings growth

- EBITDA<sup>1</sup> of \$7.8m (+\$2.0m vs pcp), with margin improving from 11% in 1H FY25 to 13% in 1H FY26.

## Positive operating cashflows

- 1H FY26 operating cashflow positive of \$2.5m.
- Free cash flow of (\$0.9) driven by budgeted manufacturing and R&D investments.




## Unit sales growth

- 1H FY26 unit sales outperformed backlog-supported 1H FY25.

<sup>1</sup> EBITDA excludes leases payments (\$1.6m), share/options expenses (\$1.5m), unrealised foreign exchange gain/(loss) (\$0.5m), one-off costs (\$0.6m - tranche 3 restructure) and discontinued operations (nil).

# Regional revenue highlights

personal use only



# Profit or loss summary

\$m	1H FY26	1H FY25	%
Revenue	60.7	53.7	+13%
<b>Gross margin</b>	<b>37.2</b>	<b>33.1</b>	<b>+13%</b>
Sales and marketing expenses	(11.8)	(11.0)	+7%
Administrative and other expenses	(10.0)	(8.5)	+18%
<b>Operating profit</b>	<b>15.4</b>	<b>13.6</b>	<b>+13%</b>
Corporate, research and business development expenses	(7.6)	(7.8)	-3%
<b>EBITDA<sup>1</sup></b>	<b>7.8</b>	<b>5.8</b>	<b>+35%</b>
Depreciation and amortisation expenses	(1.4)	(1.7)	-14%
Leases	(1.6)	(1.4)	+14%
Other <sup>2</sup>	(2.7)	(1.2)	>+100%
<b>PBT</b>	<b>2.1</b>	<b>1.5</b>	<b>+43%</b>
Tax	(1.3)	(1.6)	-18%
<b>NPAT</b>	<b>0.8</b>	<b>(0.1)</b>	<b>&gt;-100%</b>
<b>Key metrics</b>	<b>1H FY26</b>	<b>1H FY25</b>	<b>%</b>
MAS (device) gross margin %	72.4%	71.6%	+1.1%
Group gross margin %	61.3%	61.6%	-0.5%
EBITDA <sup>1</sup> margin	13%	11%	20%
Underlying EBITDA <sup>3</sup>	6.2	4.4	+42%

## Revenue

- Double digit growth in Europe and North America.
- Driven by robust demand, continued capacity uplifts, and reduction in turnaround time.

## Costs

- Continued drive for operating leverage, with budgeted operational and personnel investments.

## EBITDA<sup>1</sup>

- Significant increase in EBITDA reflects disciplined cost management.
- Budgeted operational and personnel investment is expected is weighted more towards H2 of FY26.

## NPAT

- Positive for current 1H FY26.

<sup>1</sup> EBITDA excludes leases payments (\$1.6m).

<sup>2</sup> Other represents the share/option expenses (\$1.5m), unrealised foreign exchange gain/(loss) (\$0.5m), one-off costs (\$0.6m - tranche 3 restructure) excluded from EBITDA.

<sup>3</sup> Underlying EBITDA represents EBITDA less leases costs.

# Balance sheet summary

\$m	31 December 2025	30 June 2025
Cash and cash equivalents	18.0	17.3
Trade and other receivables	18.2	18.5
Inventories	7.6	7.4
Property, plant and equipment	7.1	7.0
Intangible assets	21.7	21.5
Right of use asset	5.6	6.9
Deferred tax assets	1.8	2.4
<b>Total assets</b>	<b>79.9</b>	<b>81.0</b>
Trade and other payables	16.6	19.5
Borrowings	0.7	0.8
Provisions	4.9	5.3
Current tax liabilities	1.7	1.8
Lease liabilities	5.9	7.2
<b>Total liabilities</b>	<b>29.9</b>	<b>34.6</b>
<b>Net assets</b>	<b>50.0</b>	<b>46.4</b>

## Cash

- Increased balance sheet strength with positive operating cash flow \$2.5m<sup>1</sup>.

## Borrowings

- Residual debt represent European government backed borrowings.

<sup>1</sup> Operating cash flow of \$2.5m includes \$1.6m of lease costs.

# Cash flow summary

\$m	1H FY26	1H FY25
<b>EBITDA<sup>1</sup></b>	<b>7.8</b>	<b>5.8</b>
Movement in working capital and other non-cash	(2.3)	(1.5)
Tax paid	(0.6)	(0.3)
One-off expenses	(0.8)	-
<b>Operating cash flow (before leases)</b>	<b>4.1</b>	<b>4.1</b>
Payment of finance leases	(1.6)	(1.4)
<b>Operating cash flow (after leases)</b>	<b>2.5</b>	<b>2.7</b>
Payments for intangible assets	(1.0)	(0.7)
Payments for property, plant and equipment	(2.4)	(0.6)
<b>Investing cash flow</b>	<b>(3.4)</b>	<b>(1.4)</b>
<b>Free cash flow</b>	<b>(0.9)</b>	<b>1.3</b>
Proceeds from repayment of loan by Employee Share Trust	2.0	-
Repayment of borrowings	(0.1)	(0.1)
<b>Financing cash flow</b>	<b>1.9</b>	<b>(0.1)</b>
<b>Net cash flow before exchange rate adjustments</b>	<b>1.0</b>	<b>1.2</b>
Exchange rate adjustments	(0.3)	1.2
<b>Net cash flow</b>	<b>0.7</b>	<b>2.3</b>

## One-off expenses

- Relates to cash settlement of prior year and current year one-off cost provisions.

## Operating and free cash flow

- Positive operating cash flow before and after leases<sup>2</sup> of \$4.1m and \$2.5m respectively.

## Investing

- Continued investments in manufacturing infrastructure and R&D.

## Employee share trust transaction

- Net \$2.0m of proceeds from repayment of loan in relation to 2.86m shares by SomnoMed's employee share trust.

## Borrowings

- Residual debt represents European government backed borrowings.

<sup>1</sup> EBITDA excludes leases payments (\$1.6m), share/option expenses (\$1.5m), unrealised foreign exchange gain/(loss) (\$0.5m), one-off costs (\$0.6m - tranche 3 restructure) and discontinued operations (nil).

<sup>2</sup> Lease cost of \$1.6m presented under financing cash flow for statutory accounts.

for personal use only

# Half-Year 2026 Results

- 1. 1H FY26 Highlights
- 2. Financials
- 3. Operations update**
- 4. FY26 outlook



# 1H FY26 Operational Highlights

## Progressed Manufacturing Expansion

- Increased manufacturing capacity by more than 20%
- Production TAT improved by over 50% from June 2025 to December 2025

## Strengthened Senior Leadership Team

- Appointed two new senior executives to strengthen global leadership capability, including new Chief Transformation Officer role to drive execution and support growth

# Leadership Strengthened with Key Appointments



## **Nathan Minnich: Chief Marketing Officer (US based)**

- Extensive global commercial and marketing leadership experience
- Deep expertise across dental, sleep, and medical technology sectors
- Senior leadership roles at Treace Medical Concepts, LivaNova, and VP Americas Marketing at Align Technology.



## **Greg Knight: Chief Transformation Officer**

- Newly created role to support the Company's next phase of growth
- Over 20 years of global medical device product, manufacturing and operations experience
- Former senior leadership roles including 15 years at ResMed

# Rest Assure®

- FDA cleared Rest Assure® as the first oral device with built-in compliance monitoring.
- Clearance includes the oral device and software platform incl. patient app, physician platform, docking station and cloud systems.
- Continuing review of FDA feedback for optimal design of proposed US-based clinical trial to support a potential FDA 510(k) submission for efficacy monitoring
- Evaluating options to accelerate commercialisation of Rest Assure® under existing FDA clearance for built-in compliance monitoring


# Half-Year 2026 Results

1. 1H FY26 Highlights

2. Financials

3. Operations update

4. FY26 outlook



# Strategy and Outlook

FY25

FY26

FY27 and beyond

## Execution and delivery – year of reset

- ✓ People and culture: build a high performing team and culture of efficiency and improvement
- ✓ Financial: generate earnings growth and positive operating cashflow
- ✓ Operational: manufacturing capacity growth, backlog at negligible level
- ✓ Customer: improved turnaround times

## Sustainable growth and investment

- Financial: sustainable revenue and margin growth
- Operational: existing manufacturing site expansion
- Innovation: Rest Assure®

## Stabilisation and innovation

- Financial: >10+% EBITDA<sup>1</sup> margins
- Operational: manufacturing second site
- Innovation: Rest Assure® commercial launch and R&D pipeline

<sup>1</sup>EBITDA excludes leases payments, share/options expenses, unrealised foreign exchange gain/(loss), one-off costs and discontinued operations.

# Reaffirming FY26 guidance

## Revenue

**\$119m-\$126m**

## EBITDA<sup>1</sup>

**\$10m-\$12m**

## Capex<sup>2</sup>


**\$6m-\$8m**

<sup>1</sup>EBITDA excludes leases payments of between \$3m-\$3.5m for full FY26, share/option expenses, unrealised foreign exchange gain/(loss), one-off costs and discontinued operations.

<sup>2</sup>Capex spend expected to approximate 20-30% on Rest Assure®, 20-30% on manufacturing site expansion, and residual on other investments including maintenance capex.

for personal use only

# Q&A





**Thank You**

**For further information please contact:**

Investor Relations: [IR@somnomed.com.au](mailto:IR@somnomed.com.au)

personal use only